MEIS1 and chronic myelogenous leukemia, BCR-ABL1 positive: During the chronic phase of CML, after single-cell trajectory reconstitution on prognosis phenotype, CD63 regulation highlighted a trajectory cluster implicating HSPB1, PIM2, ANXA5, LAMTOR1, CFL1, CD52, RAD52, MEIS1, and PDIA3 molecules characterizing hematopoietic malignancies like myelodysplasia, acute myeloid leukemia, and acute lymphoid leukemia.